parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in hematopoietic stem cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 56	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 15607

MORC1 in dopamine neurons, braak-0.26 (p 0.499) → +0.57 (p 0.109)receipt 15616
MORC1 in microglia, braak-0.30 (p 0.428) → -0.34 (p 0.371)receipt 15615

receipt 15616: MORC1 in dopamine neurons, braak

power: full sample +0.18 (p 0.487, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.19 (p 0.439, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.19 (p 0.439, n 18). could be the mix.
skeptic: leave-one-out range +0.05 to +0.34, sign flips 0; without severely affected donors +0.18 (p 0.487, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MORC1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 15615: MORC1 in microglia, braak

power: full sample -0.28 (p 0.258, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.26 (p 0.306, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.28 (p 0.265, n 18). could be the mix.
skeptic: leave-one-out range -0.42 to -0.17, sign flips 0; without severely affected donors -0.28 (p 0.258, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MORC1 in microglia.

case closed: nothing better to follow up.

loading the receipts